BeOne Medicines (BEIGF) Non Operating Income (2016 - 2026)

BeOne Medicines (BEIGF) has 11 years of Non Operating Income data on file, last reported at $14.5 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $14.5 million, up 268.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$32.0 million (down 205.9% YoY), and the FY2025 annual result was -$42.6 million, down 236.71% from the prior year.
• Non Operating Income rose to $14.5 million in Q1 2026 per BEIGF's latest filing, from -$35.7 million in the prior quarter.
• Over five years, Non Operating Income peaked at $336.7 million in Q3 2023 and troughed at -$129.6 million in Q2 2022.
• A 5-year average of $2.6 million and a median of $4.0 million in 2025 frame the typical range for Non Operating Income.
• On a YoY basis, Non Operating Income climbed as much as 390.25% in 2022 and fell as far as 14850.06% in 2022.
• A 5-year view of Non Operating Income shows it stood at $19.4 million in 2022, then declined by 13.83% to $16.7 million in 2023, then slumped by 182.0% to -$13.7 million in 2024, then tumbled by 159.87% to -$35.7 million in 2025, then soared by 140.73% to $14.5 million in 2026.
• Business Quant data shows BEIGF's Non Operating Income at $14.5 million in Q1 2026, -$35.7 million in Q4 2025, and -$19.0 million in Q3 2025.